About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

United Therapeutics agreed to acquire biotech firm Thymmune Therapeutics for $140m in cash.

2026-07-02

United Therapeutics agreed to acquire biotech firm Thymmune Therapeutics for $140m in cash.

Other News
2026-07-02

Nasdaq 100 futures fell 1%, the Nasdaq erased earlier gains and is now down 0.2%, the S&P 500's gains narrowed to 0.2%, and the Dow Jones is currently up 0.7%.

Nasdaq 100 futures fell 1%, the Nasdaq erased earlier gains and is now down 0.2%, the S&P 500's gains narrowed to 0.2%, and the Dow Jones is currently up 0.7%.
2026-07-02

Russian presidential spokesman Dmitry Peskov said on July 2 that Chief of the General Staff Valery Gerasimov briefed President Putin on the results of large-scale retaliatory strikes on Kyiv and other locations; Peskov said the strikes targeted milit

Russian presidential spokesman Dmitry Peskov said on July 2 that Chief of the General Staff Valery Gerasimov briefed President Putin on the results of large-scale retaliatory strikes on Kyiv and other locations; Peskov said the strikes targeted military or quasi-military facilities. The Ukrainian air force said it recorded 74 missiles and 496 drones launched by Russia between 18:00 on July 1 and the early hours of July 2, including four Zircon hypersonic cruise missiles, and reported 17 dead and more than 90 wounded. The Russian defense ministry said the strikes, launched in response to alleged Ukrainian attacks on Russian civilian infrastructure, hit military‑industrial and energy facilities in Kyiv city and region and military airfields elsewhere; it said Russia’s air defenses intercepted and destroyed 327 Ukrainian drones between 20:00 on July 1 and 07:00 on July 2, Moscow time.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.